Hemab: $55M series A for Novo vets developing bispecific for rare bleeding disorders

Launched by a co-founding team that includes a pair of Novo Nordisk veterans, Hemab is advancing a bispecific antibody the pharma had de-prioritized with the goal of addressing rare bleeding disorders beyond hemophilia.

Hemab ApS revealed its $55 million series A round on Thursday, with Novo Holdings A/S, HealthCap and RA Capital funding the start-up. Although CEO Benny Sorensen said the process of forming the company began more than two years ago, it was only late last year that the company “refined the business case” and landed a seed round of undisclosed size from Novo Seeds...